— Know what they know.
Not Investment Advice
Also trades as: 0HTG.L (LSE) · $vol 0M

CAH NYSE

Cardinal Health, Inc.
1W: +3.2% 1M: +0.1% 3M: -10.6% YTD: -2.5% 1Y: +30.5% 3Y: +144.5% 5Y: +297.7%
$200.68
+0.07 (+0.03%)
 
Weekly Expected Move ±5.0%
$176 $185 $195 $205 $215
NYSE · Healthcare · Medical - Distribution · Alpha Radar Neutral · Power 57 · $47.0B mcap · 234M float · 0.845% daily turnover · Short 61% of daily vol

Edge Score

Quantitative competitive moat analysis scoring five pillars of durable advantage — cost leadership, brand intangibles, switching costs, network effects, and efficient scale — using industry percentile rankings on a 0–100 scale.

WEAK EDGE
53.4 / 100
NoneWeakNarrowWide
Primary source: Efficient Scale  ·  ROIC: 69.3%
Cost Advantage
67
Intangibles
33
Switching Cost
43
Network Effect
60
Scale ★
80
The Edge Score quantifies a company's competitive moat using five pillars: Cost Advantage (20%, operating margin and SG&A efficiency vs industry peers), Intangible Assets (25%, gross margin premium, R&D intensity, brand pricing power), Switching Costs (25%, revenue stability, earnings consistency, customer retention proxied by operating leverage), Network Effects (15%, revenue growth with expanding margins, market share dominance), and Efficient Scale (15%, market concentration, ROIC sustainability). Each pillar is scored 0–100 using industry percentile rankings, then weighted into a composite. Wide ≥ 70, Narrow ≥ 55, Weak ≥ 40, None < 40. CAH shows a Weak competitive edge (53.4/100) — limited structural advantages that may face competitive pressure. The primary source of advantage is Efficient Scale. ROIC of 69.3% confirms the company is generating returns well above its cost of capital — a hallmark of durable competitive advantages.

Analyst Insights

Wall Street analyst consensus based on price targets and buy/sell/hold recommendations from institutional research coverage over the trailing 12 months.

Analyst Price Targets
$248
Low
$248
Avg Target
$248
High
Based on 1 analyst since Apr 30, 2026 earnings
Analyst Recommendations
Strong Buy: 0Buy: 18Hold: 15Sell: 0Strong Sell: 0
Rating Summary
ConsensusBuy
Avg Target$255.25
Analysts4
Price Target Change History
DateFirmAnalystOldNewChangeUpside @ CallStock@Call
2026-05-01 Robert W. Baird $252 $248 -4 +27.1% $195.08
2026-04-08 Evercore ISI Elizabeth Anderson $260 $240 -20 +11.6% $215.13
2026-03-09 Leerink Partners Michael Cherny $240 $275 +35 +23.7% $222.28
2026-02-24 Barclays $243 $258 +15 +14.8% $224.82
2026-02-10 Wells Fargo $179 $256 +77 +13.4% $225.76
2026-02-06 Morgan Stanley $245 $255 +10 +11.0% $229.63
2026-02-06 Robert W. Baird $250 $252 +2 +10.1% $228.78
2026-02-06 UBS Kevin Caliendo $220 $260 +40 +13.7% $228.63
2026-02-06 Mizuho Securities Steven Valiquette $222 $235 +13 +3.4% $227.18
2026-02-05 Evercore ISI Elizabeth Anderson $220 $260 +40 +14.4% $227.18
2026-01-29 Morgan Stanley Erin Wright $181 $245 +64 +16.5% $210.39
2026-01-14 Robert W. Baird Eric Coldwell $232 $250 +18 +17.9% $211.97
2026-01-13 Leerink Partners Michael Cherny $186 $240 +54 +15.3% $208.24
2026-01-12 Mizuho Securities Steven Valiquette $210 $222 +12 +10.4% $201.11
2025-12-08 Barclays Glen Santangelo $63 $243 +180 +22.2% $198.88
2025-11-03 Mizuho Securities Steven Valiquette $110 $210 +100 +10.4% $190.22
2025-11-03 Jefferies $150 $220 +70 +15.7% $190.22
2025-10-31 Evercore ISI Elizabeth Anderson $115 $220 +105 +15.0% $191.29
2025-10-31 UBS $78 $220 +142 +14.5% $192.07
2025-10-31 Robert W. Baird $140 $232 +92 +20.6% $192.36
2025-08-22 Argus Research $148 $189 +41 +27.6% $148.10
2025-08-12 Leerink Partners Michael Cherny Initiated $186 +27.1% $146.30
2025-08-11 Jefferies Brian Tanquilut Initiated $150 -4.9% $157.66
2025-06-13 Morgan Stanley Erin Wright $119 $181 +62 +12.1% $161.41
2025-06-03 Wells Fargo Stephen Baxter $101 $179 +78 +15.1% $155.48
2025-02-04 Argus Research Kristina Ruggeri $125 $148 +23 +18.2% $125.17
2024-09-23 Robert W. Baird Eric Coldwell $137 $140 +3 +24.7% $112.30
2024-09-11 Argus Research David Toung $115 $125 +10 +11.2% $112.36
2024-08-16 Deutsche Bank George Hill $51 $119 +68 +10.3% $107.91
2024-08-15 Evercore ISI Elizabeth Anderson $68 $115 +47 +6.8% $107.71
2024-08-15 Morgan Stanley Erin Wright $90 $119 +29 +11.9% $106.36
2024-08-15 Mizuho Securities Ann Hynes Initiated $110 +2.4% $107.39
2024-08-15 Robert W. Baird Eric Coldwell $129 $137 +8 +27.6% $107.33
2024-08-15 Wells Fargo Stephen Baxter Initiated $101 -5.0% $106.36
2024-06-11 CFRA Garrett Nelson Initiated $111 +12.1% $99.01
2024-05-29 Robert W. Baird Eric Coldwell $128 $129 +1 +36.1% $94.75
2024-05-15 Argus Research David Toung Initiated $115 +18.0% $97.43
2024-05-03 Robert W. Baird Eric Coldwell $134 $128 -6 +24.3% $102.98
2024-04-05 Robert W. Baird Eric Coldwell $94 $134 +40 +21.7% $110.12
2023-08-14 Morgan Stanley Erin Wright $86 $90 +4 -3.2% $92.99
2023-02-07 Robert W. Baird Baird Baird Initiated $94 +19.6% $78.61
2023-02-03 Credit Suisse $79 $92 +13 +14.8% $80.14
2023-01-06 Morgan Stanley $74 $86 +12 +10.1% $78.12
2022-11-22 Credit Suisse Initiated $79 -0.3% $79.22
2022-08-29 UBS $61 $78 +17 +13.9% $68.51
2022-05-20 Evercore ISI Elizabeth Anderson Initiated $68 +21.8% $55.83
2022-05-08 Deutsche Bank George Hill Initiated $51 -12.5% $58.27
2022-04-16 Morgan Stanley Ricky Goldwasser Initiated $74 +17.5% $62.96
2022-01-16 Barclays Steve Valiquette Initiated $63 +18.7% $53.09
2021-11-16 UBS Kevin Caliendo Initiated $61 +24.9% $48.84

Financial Rating

Composite financial health rating (A+ to F) based on discounted cash flow valuation, return on equity, return on assets, debt-to-equity leverage, and relative P/E and P/B multiples.

C+
May 22, 2026
DCF
4
ROE
1
ROA
4
D/E
1
P/E
1
P/B
1
The Financial Rating evaluates six fundamental factors — discounted cash flow (DCF) valuation, return on equity (ROE), return on assets (ROA), debt-to-equity leverage (D/E), and relative price-to-earnings (P/E) and price-to-book (P/B) multiples — each scored 1–5. CAH receives an overall rating of C+. Strongest factors: DCF (4/5), ROA (4/5). Areas of concern: ROE (1/5), D/E (1/5), P/E (1/5), P/B (1/5).
Rating Change History
DateFromTo
2026-04-22 B- C+
2026-04-01 C+ B-

InsiderStreet Scorecard

Proprietary multi-factor scorecard rating companies across seven fundamental dimensions — profitability, balance sheet strength, earnings quality, growth, value, momentum, and safety — each scored 0–100.

59 Grade C
Profitability
6
Balance Sheet
42
Earnings Quality
77
Growth
76
Value
43
Momentum
91
Safety
100
Cash Flow
57
The InsiderStreet Scorecard rates companies across eight dimensions: Profitability (margins, ROA, ROE), Balance Sheet (leverage, liquidity, coverage), Earnings Quality (accruals, cash conversion), Growth (revenue and earnings trajectory), Value (P/E, P/B, earnings yield, Graham criteria), Momentum (revenue and earnings acceleration), Safety (Altman Z-Score risk adjustment), and Cash Flow (operating cash flow quality, FCF conversion, cash coverage). The overall score blends 35% quality, 35% value, and 30% momentum, with a penalty for distress-zone Altman scores. CAH scores highest in Safety (100/100) and lowest in Profitability (6/100). A grade of C represents mixed fundamentals — strengths in some areas offset by weaknesses.

Risk & Quality Signals

Academic financial models used by institutional investors to assess bankruptcy risk, earnings manipulation, financial strength, and credit quality.

Altman Z-Score
5.24
Safe Zone
Piotroski F-Score
7/9
Beneish M-Score
-2.49
Unlikely Manipulator
Ohlson O-Score
-6.95
Bankruptcy prob: 0.1%
Low Risk
Credit Rating
B-
Score: 20.0/100
Trend: Deteriorating
Earnings Quality
75/100
OCF/NI: 3.66x
Accruals: -9.0%
The Altman Z-Score (1968) combines five ratios — working capital, retained earnings, EBIT, market value of equity, and sales, all relative to total assets or liabilities — into a single bankruptcy predictor. CAH scores 5.24, placing it in the Safe Zone (safe > 2.99, distress < 1.81). Bankruptcy is statistically unlikely within the next two years. The Piotroski F-Score (2000) is a 9-point binary checklist — four profitability tests (positive ROA, positive cash flow, improving ROA, cash flow exceeding net income), three leverage tests (declining debt ratio, improving current ratio, no share dilution), and two efficiency tests (improving gross margin, improving asset turnover). Each pass scores 1 point. CAH scores 7/9, signaling strong financial health across all three dimensions. The Beneish M-Score (1999) is an 8-variable model that detects earnings manipulation by comparing year-over-year changes in receivables, gross margins, asset quality, sales growth, depreciation, SG&A, leverage, and accruals. Scores above −1.78 statistically resemble past manipulators. CAH's score of -2.49 falls below this threshold, suggesting earnings are unlikely to be manipulated. The Ohlson O-Score (1980) is a 9-variable logistic regression that estimates bankruptcy probability using firm size, leverage, working capital, current ratio, profitability (ROA), cash flow coverage, negative equity flag, consecutive losses flag, and earnings trajectory. The raw score is converted to a probability via logistic transformation. CAH's implied 0.1% bankruptcy probability is well within safe territory. Our Credit Rating model scores companies on five weighted components — solvency (30%), earning power (25%), leverage (20%), liquidity (15%), and cash flow quality (10%) — then blends the absolute score with sector and industry peer rankings. For companies with large buyback programs, equity is adjusted by adding back cumulative 5-year repurchases (capped at 80% of FCF generated) to avoid penalizing shareholder-friendly capital allocation. CAH receives an estimated rating of B- (score: 20.0/100), with a deteriorating trend. The Earnings Quality score measures how well reported earnings are backed by real cash. It evaluates the operating cash flow to net income ratio (OCF/NI ≥ 1.0 means every dollar of earnings is cash-backed) and the accruals ratio (the gap between earnings and cash flow relative to assets — lower is better). CAH's score of 75/100 is high — cash flows strongly support reported earnings.

Valuation

Key valuation multiples comparing the stock's market price to its earnings, revenue, book value, and cash flows. Lower multiples may indicate relative undervaluation versus peers.

P/E
30.25x
PEG
14.96x
P/S
0.19x
P/B
-16.65x
P/FCF
8.82x
P/OCF
7.96x
EV/EBITDA
16.73x
EV/Revenue
0.22x
EV/EBIT
22.36x
EV/FCF
9.82x
Earnings Yield
3.43%
FCF Yield
11.33%
Shareholder Yield
1.78%
Graham Number
Equity-based multiples (P/E, P/B, P/FCF) compare the stock price to per-share fundamentals and are affected by capital structure. Enterprise value multiples (EV/EBITDA, EV/Revenue, EV/FCF) strip out debt and cash, making them more useful for cross-company comparisons regardless of how companies are financed. The Graham Number — √(22.5 × EPS × Book Value) — is Benjamin Graham's formula for the maximum price a defensive investor should pay. At 30.3x earnings, CAH commands a growth premium.

DuPont Decomposition (5-Factor)

The 5-factor DuPont framework breaks Return on Equity into its component drivers — tax efficiency, interest burden, operating profitability, asset utilization, and financial leverage — to reveal what truly drives shareholder returns.

Tax Burden
0.732
NI / EBT
×
Interest Burden
0.942
EBT / EBIT
×
EBIT Margin
0.010
EBIT / Rev
×
Asset Turnover
4.977
Rev / Assets
×
Equity Multiplier
-16.390
Assets / Equity
=
ROE
-55.6%
The 5-factor DuPont identity decomposes ROE as: Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Equity Multiplier = ROE. This reveals whether returns are driven by operating performance, financial leverage, or tax efficiency — three very different sources of profitability. CAH's ROE of -55.6% is driven by Asset Turnover (4.977), indicating efficient use of assets to generate revenue.

Graham-Dodd Adjusted Valuation

Our adaptation of Graham's growth formula (Fair P/E = 8.5 + 2g) from The Intelligent Investor. The classic version relies on analyst growth projections, which can be unreliable. This adjusted model substitutes the company's realized 3-year EPS CAGR — a backward-looking, verifiable measure of actual earnings power — grounding the valuation in demonstrated performance rather than forecasts.

Adj. Growth Rate
30.10%
Fair P/E
68.69x
Intrinsic Value
$482.89
Price/Value
0.42x
Margin of Safety
57.55%
Premium
-57.55%
Assessment
Undervalued
Graham's classic formula uses analyst-projected growth to estimate a fair P/E (8.5 + 2g). Our adjusted version replaces that projection with CAH's realized 30.1% 3-year EPS CAGR — what the company actually delivered, not what analysts hope for. At an intrinsic value of $482.89, CAH appears undervalued with a 58% margin of safety. The adjusted fair P/E of 68.7x compares to the current market P/E of 30.3x.

Profitability Trends

Historical profitability ratios tracking how efficiently the company converts revenue into returns for shareholders over time.

Leverage & Solvency Trends

Debt and liquidity metrics showing the company's financial leverage and ability to meet short-term and long-term obligations.

Efficiency & Working Capital Trends

Operating efficiency metrics measuring how quickly the company converts inventory to sales, collects receivables, and manages its cash conversion cycle.

Growth Trends (YoY %)

Year-over-year growth rates for key financial metrics, showing the trajectory of revenue, earnings, and cash flow generation.

Earnings Stability

R-squared of linear regression measuring how predictably revenue, earnings, and margins follow a trend over the trailing 5 years. 1.0 = perfectly predictable; lower values indicate erratic or cyclical behavior.

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 1800 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price
$200.68
Median 1Y
$241.63
5th Pctile
$149.26
95th Pctile
$390.75
Ann. Volatility
29.2%
Analyst Target
$255.25
25th–75th percentile 5th–95th percentile Median path Historical Analyst target

Executive Compensation

C-suite compensation breakdown including salary, stock awards, options, and incentive pay. The CEO-to-employee pay ratio and Gini coefficient measure pay distribution fairness.

C-Suite Compensation

ExecutiveSalaryStockTotal
Jason M. Hollar
Chief Executive Officer
$1,492,329 $13,431,441 $18,976,195
Aaron E. Alt
Chief Financial Officer
$871,164 $3,977,813 $6,210,035
Deborah L. Weitzman
Chief Executive Officer, Pharmaceutical and Specialty Solutions Segment
$741,932 $3,771,217 $5,507,857
Jessica L. Mayer
Chief Legal and Compliance Officer
$716,932 $3,202,943 $4,925,352
Stephen M. Mason
Chief Executive Officer, Global Medical Products and Distribution Segment
$741,932 $3,357,917 $4,745,044

CEO Pay Ratio

203:1
CEO-to-Employee Pay Ratio
CEO Total Comp: $18,976,195
Avg Employee Cost (SGA/emp): $93,276
Employees: 57,700

C-Suite Pay Equality (Gini)

CEO Compensation Mix

Workforce & Productivity

Workforce efficiency metrics measuring revenue, profit, and R&D spend per employee — key indicators of operational leverage and human capital productivity.

Employees
57,700
+18.0% YoY
Revenue / Employee
$3,857,504
Rev: $222,578,000,000
Profit / Employee
$27,054
NI: $1,561,000,000
SGA / Employee
$93,276
Avg labor cost proxy

Scaling Efficiency

All Ratios & Metrics

Complete fundamental data with up to 20 periods of history, sparkline trends, and current values across 13 categories and 130+ financial metrics.

Profitability
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
ROE 28.4% 34.1% 63.4% 31.0% -53.3% -1.7% -2.0% -2.4% 85.6% -14.2% -7.6% -34.7% -30.2% -27.6% -41.5% -42.6% -50.5% -52.1% -53.2% -55.6% -55.59%
ROA 2.8% 1.4% 2.7% 1.3% -2.2% -2.1% -2.5% -2.9% 1.0% 0.6% 0.3% 1.5% 1.3% 1.9% 2.9% 3.0% 3.5% 3.2% 3.2% 3.4% 3.39%
ROIC 11.3% 17.5% 24.9% 1.5% -7.3% -1.2% -1.8% -9.0% 1.6% -16.1% -8.7% -35.9% -31.4% -32.3% -48.4% -50.8% -60.8% 63.2% 65.7% 69.3% 69.31%
ROCE 7.0% 3.0% 9.1% 0.7% -2.8% -4.7% -6.7% -0.5% 4.5% 7.6% 5.9% 12.4% 10.3% 13.1% 19.5% 19.8% 23.7% 16.3% 17.0% 17.0% 16.99%
Gross Margin 4.6% 3.5% 3.7% 3.6% 3.8% 3.4% 3.3% 3.2% 3.5% 3.4% 3.2% 3.2% 3.5% 3.1% 3.6% 3.5% 3.9% 3.7% 3.6% 3.4% 3.38%
Operating Margin 1.2% 0.4% 0.9% -2.1% -0.2% 0.1% 0.3% -0.2% 1.1% 0.3% -0.1% 0.9% 0.7% 0.7% 1.1% 1.0% 1.3% 0.7% 1.0% 1.1% 1.08%
Net Margin 0.3% 0.3% 0.6% 0.1% -3.1% 0.3% 0.2% -0.3% 0.7% -0.1% -0.0% 0.6% 0.5% 0.4% 0.8% 0.7% 0.9% 0.4% 0.7% 0.7% 0.72%
EBITDA Margin 1.7% 0.8% 1.3% -1.7% 0.2% 0.4% 0.6% 0.1% 1.5% 0.6% 0.3% 1.2% 1.0% 1.0% 1.4% 1.3% 1.7% 1.1% 1.4% 1.1% 1.08%
FCF Margin 1.0% 1.2% 0.7% 0.7% 0.3% 1.5% 1.8% 1.4% 2.3% 1.2% 1.4% 1.6% 0.9% 1.4% 0.5% -0.2% 1.1% 0.8% 1.9% 2.3% 2.25%
OCF Margin 1.3% 1.5% 0.9% 0.9% 0.4% 1.7% 2.0% 1.7% 2.5% 1.4% 1.6% 1.8% 1.2% 1.7% 0.7% 0.0% 1.3% 1.1% 2.1% 2.5% 2.50%
ROA 3Y Avg snapshot only 2.51%
ROIC Economic snapshot only 69.31%
Cash ROA snapshot only 11.49%
Cash ROIC snapshot only 2.27%
CROIC snapshot only 2.05%
NOPAT Margin snapshot only 0.76%
Pretax Margin snapshot only 0.93%
R&D / Revenue snapshot only 0.00%
SGA / Revenue snapshot only 2.36%
SBC / Revenue snapshot only 0.15%
Valuation
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
P/E Ratio 13.90 24.73 11.48 24.00 -15.17 -14.45 -15.72 -14.98 40.24 88.49 150.14 37.83 48.40 27.57 20.74 21.58 21.10 25.67 23.44 29.16 30.250
P/S Ratio 0.10 0.09 0.08 0.08 0.08 0.07 0.09 0.10 0.09 0.11 0.10 0.11 0.12 0.10 0.12 0.13 0.15 0.18 0.16 0.20 0.188
P/B Ratio 8.94 8.44 7.28 7.44 8.08 -19.00 -24.24 -26.88 -26.28 -7.81 -7.06 -8.15 -9.05 -7.32 -8.27 -8.82 -10.23 -14.41 -13.45 -17.47 -16.652
P/FCF 10.03 7.45 11.60 11.85 32.46 4.92 5.05 6.83 4.10 9.79 7.35 7.10 13.36 7.25 24.76 -57.70 13.48 21.66 8.40 8.82 8.824
P/OCF 7.98 6.22 8.61 8.93 18.21 4.31 4.53 5.97 3.75 8.14 6.24 6.14 10.55 6.26 16.80 9443.79 11.15 16.71 7.45 7.96 7.960
EV/EBITDA 9.84 14.32 7.18 19.98 77.32 202.19 -91.83 31.93 15.21 17.00 17.49 13.35 16.51 12.28 10.52 11.00 11.05 14.66 13.14 16.73 16.730
EV/Revenue 0.13 0.11 0.10 0.10 0.10 0.08 0.10 0.10 0.10 0.12 0.10 0.12 0.13 0.11 0.12 0.13 0.15 0.20 0.18 0.22 0.221
EV/EBIT 16.61 36.62 10.68 137.42 -38.41 -23.48 -20.44 -287.84 32.81 33.10 39.02 21.18 28.20 19.29 14.62 15.31 14.82 19.66 17.70 22.36 22.364
EV/FCF 12.55 9.08 14.54 14.79 39.87 5.32 5.37 7.22 4.34 10.26 7.73 7.43 13.91 7.39 25.21 -58.67 13.67 24.61 9.63 9.82 9.817
Earnings Yield 7.2% 4.0% 8.7% 4.2% -6.6% -6.9% -6.4% -6.7% 2.5% 1.1% 0.7% 2.6% 2.1% 3.6% 4.8% 4.6% 4.7% 3.9% 4.3% 3.4% 3.43%
FCF Yield 10.0% 13.4% 8.6% 8.4% 3.1% 20.3% 19.8% 14.6% 24.4% 10.2% 13.6% 14.1% 7.5% 13.8% 4.0% -1.7% 7.4% 4.6% 11.9% 11.3% 11.33%
PEG Ratio snapshot only 14.962
EV/OCF snapshot only 8.857
EV/Gross Profit snapshot only 6.104
Acquirers Multiple snapshot only 21.340
Shareholder Yield snapshot only 1.78%
Leverage & Solvency
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Current Ratio 1.10 1.12 1.12 1.12 1.12 1.08 1.08 1.08 1.08 1.00 1.00 1.00 1.00 0.98 0.98 0.98 0.98 0.94 0.94 0.94 0.935
Quick Ratio 0.54 0.60 0.60 0.60 0.60 0.57 0.57 0.57 0.57 0.52 0.52 0.52 0.52 0.56 0.56 0.56 0.56 0.50 0.50 0.50 0.502
Debt/Equity 3.79 3.75 3.75 3.75 3.75 -8.19 -8.19 -8.19 -8.19 -1.75 -1.75 -1.75 -1.75 -1.75 -1.75 -1.75 -1.75 -3.36 -3.36 -3.36 -3.360
Net Debt/Equity 2.24 1.85 1.85 1.85 1.85
Debt/Assets 0.17 0.15 0.15 0.15 0.15 0.13 0.13 0.13 0.13 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.18 0.18 0.18 0.176
Debt/EBITDA 3.33 5.22 2.95 8.07 29.20 80.62 -29.17 9.20 4.48 3.64 4.12 2.74 3.07 2.87 2.18 2.14 1.86 3.01 2.86 2.89 2.892
Net Debt/EBITDA 1.97 2.57 1.45 3.98 14.38 15.11 -5.47 1.72 0.84 0.77 0.88 0.58 0.65 0.24 0.19 0.18 0.16 1.76 1.68 1.69 1.693
Interest Coverage 6.51 2.79 8.74 0.73 -2.91 -4.16 -6.67 -0.57 5.37 7.86 7.13 20.88 17.33 27.04 27.61 19.00 15.52 10.77 9.21 7.65 7.649
Equity Multiplier 22.79 24.82 24.82 24.82 24.82 -61.89 -61.89 -61.89 -61.89 -14.65 -14.65 -14.65 -14.65 -14.04 -14.04 -14.04 -14.04 -19.10 -19.10 -19.10 -19.102
Cash Ratio snapshot only 0.100
Debt Service Coverage snapshot only 10.225
Cash to Debt snapshot only 0.415
FCF to Debt snapshot only 0.589
Defensive Interval snapshot only 988.2 days
Efficiency & Turnover
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Asset Turnover 3.83 3.81 3.93 4.02 4.15 4.11 4.23 4.37 4.50 4.70 4.82 4.95 5.05 5.12 5.07 5.02 5.02 4.53 4.77 4.98 4.977
Inventory Turnover 11.50 11.20 11.56 11.86 12.26 11.57 11.94 12.34 12.70 12.48 12.79 13.15 13.42 14.11 13.95 13.80 13.79 13.49 14.20 14.83 14.825
Receivables Turnover 18.74 18.71 19.27 19.73 20.37 18.45 19.02 19.63 20.21 18.92 19.39 19.94 20.34 19.55 19.34 19.15 19.16 17.58 18.50 19.31 19.307
Payables Turnover 6.98 6.91 7.13 7.31 7.56 6.88 7.10 7.34 7.55 6.94 7.12 7.32 7.47 7.11 7.03 6.95 6.95 6.45 6.79 7.09 7.090
DSO 19 20 19 19 18 20 19 19 18 19 19 18 18 19 19 19 19 21 20 19 18.9 days
DIO 32 33 32 31 30 32 31 30 29 29 29 28 27 26 26 26 26 27 26 25 24.6 days
DPO 52 53 51 50 48 53 51 50 48 53 51 50 49 51 52 52 53 57 54 51 51.5 days
Cash Conversion Cycle -1 -1 -1 -1 -1 -2 -2 -2 -2 -4 -4 -4 -4 -7 -7 -7 -7 -9 -8 -8 -8.0 days
Fixed Asset Turnover snapshot only 85.545
Operating Cycle snapshot only 43.5 days
Cash Velocity snapshot only 63.110
Capital Intensity snapshot only 0.217
Growth (YoY)
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Revenue 1.9% 6.2% 8.2% 9.5% 13.0% 11.6% 11.7% 12.7% 12.3% 13.0% 12.3% 11.9% 10.9% 10.6% 6.8% 2.8% 0.8% -1.8% 4.5% 10.1% 10.07%
Net Income 1.3% 1.2% 16.6% -59.8% -1.8% -2.5% -2.0% -3.3% 1.5% 1.3% 1.1% 1.5% 19.4% 2.3% 8.2% 1.1% 1.8% 83.0% 24.5% 26.9% 26.88%
EPS 1.3% 1.2% 18.3% -57.8% -1.9% -2.6% -2.0% -3.5% 1.5% 1.3% 1.1% 1.5% 25.8% 2.4% 8.4% 1.1% 1.9% 86.8% 27.6% 30.1% 30.10%
FCF -13.9% 28.0% -55.1% -62.6% -72.0% 34.8% 2.0% 1.5% 9.2% -13.8% -16.5% 21.6% -55.9% 37.7% -62.2% -1.1% 21.8% -43.0% 3.1% 12.2% 12.21%
EBITDA 1.6% 1.5% 13.2% -60.6% -88.7% -94.4% -1.1% -24.2% 4.6% 18.8% 7.3% 2.0% 30.2% 37.3% 1.0% 38.7% 78.7% 59.0% 26.9% 23.4% 23.41%
Op. Income 1.1% 1.1% 1.8% -85.1% -1.8% -2.3% -1.6% -1.4% 2.3% 2.2% 1.6% 28.5% 56.4% 71.9% 2.3% 60.2% 1.3% 82.0% 28.4% 33.7% 33.74%
OCF Growth snapshot only 2033.33%
Asset Growth snapshot only 17.73%
Debt Growth snapshot only 66.61%
Shares Change snapshot only -2.47%
Dividend Growth snapshot only 0.20%
Growth (CAGR)
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Revenue 3Y 5.2% 5.9% 6.3% 6.5% 7.2% 7.6% 8.2% 8.8% 9.0% 10.3% 10.7% 11.4% 12.1% 11.7% 10.3% 9.0% 7.9% 7.1% 7.8% 8.2% 8.20%
Revenue 5Y 5.9% 6.0% 5.9% 6.1% 6.6% 6.9% 7.4% 7.8% 8.1% 8.4% 8.5% 8.8% 9.0% 9.3% 8.7% 8.2% 7.7% 7.8% 8.7% 9.3% 9.34%
EPS 3Y -10.1% 36.0% 17.8% -44.9% -17.9% -16.8% 18.6% 10.0% 39.9%
EPS 5Y -1.4% -13.7% -1.4% -14.2% -19.7% 4.4% -25.4% 2.0% -5.2% 15.0% 8.5% 8.45%
Net Income 3Y -12.1% 33.5% 15.6% -47.7% -22.8% -21.7% 11.8% 4.1% 33.2%
Net Income 5Y -3.7% -15.6% -3.5% -16.3% -22.9% 0.3% -28.3% 1.8% -8.9% 10.4% 3.8% 3.81%
EBITDA 3Y -8.2% 4.3% 10.1% -21.9% -48.1% -71.3% -14.5% -3.6% -6.0% 15.0% 4.1% 46.5% 1.4% 2.5% 72.4% 72.36%
EBITDA 5Y -7.3% -16.1% -5.7% -22.7% -40.2% -52.1% -24.7% -13.2% 4.6% -5.9% 1.6% 0.5% -8.5% 10.2% 8.9% 8.90%
Gross Profit 3Y -0.8% -1.9% -2.2% -2.4% -2.4% -1.4% -1.6% -1.3% -1.4% 0.1% 0.5% 1.1% 2.2% 2.9% 4.0% 5.3% 6.8% 7.7% 9.6% 10.5% 10.49%
Gross Profit 5Y 1.7% 0.7% 0.5% -0.0% -0.5% 0.0% -0.3% -0.9% -1.2% -0.8% -0.4% 0.4% 1.3% 1.5% 1.9% 2.2% 2.4% 3.5% 4.5% 4.9% 4.92%
Op. Income 3Y -29.4% 54.9% 30.4% -49.7% 1.0% 20.9% 19.1% 38.4% 7.0% 1.7%
Op. Income 5Y -24.7% -28.1% -8.6% -46.8% -17.6% 41.8% -3.9% 8.5% 7.8% -9.5% 34.4% 30.5% 30.51%
FCF 3Y -15.0% -5.2% -10.7% -13.1% -43.2% 4.5% 35.7% 18.7% 34.9% 14.2% 4.3% 4.2% 7.9% 17.0% -1.5% 76.2% -12.2% 9.4% 25.4% 25.40%
FCF 5Y -10.4% -4.1% -15.7% -8.1% -6.6% 28.0% 12.3% 11.2% 11.8% -0.2% 12.5% 14.7% -3.9% 6.3% -4.7% 5.7% 3.1% 12.2% 12.9% 12.89%
OCF 3Y -12.0% -4.3% -8.1% -10.0% -34.0% 4.7% 30.5% 16.3% 30.7% 13.1% 5.1% 4.9% 8.2% 15.6% 1.5% -87.4% 54.8% -8.4% 9.8% 24.1% 24.10%
OCF 5Y -8.9% -3.9% -13.5% -7.6% -6.3% 21.4% 10.9% 10.0% 11.1% 0.5% 11.4% 13.9% -1.7% 6.7% -1.5% -72.8% 5.8% 4.1% 11.7% 12.4% 12.39%
Assets 3Y 0.5% 3.6% 3.6% 3.6% 3.6% 2.3% 2.3% 2.3% 2.3% 2.1% 2.1% 2.1% 2.1% 0.5% 0.5% 0.5% 0.5% 6.6% 6.6% 6.6% 6.58%
Assets 5Y 6.2% 5.4% 5.4% 5.4% 5.4% 1.8% 1.8% 1.8% 1.8% 1.6% 1.6% 1.6% 1.6% 2.0% 2.0% 2.0% 2.0% 5.4% 5.4% 5.4% 5.44%
Equity 3Y -35.9% -33.4% -33.4% -33.4% -33.4%
Book Value 3Y -34.5% -32.1% -32.1% -31.9% -31.5%
Dividend 3Y 2.5% 2.1% 2.3% 2.3% 2.4% 2.1% 1.3% 2.1% 2.4% 2.8% 3.0% 4.1% 4.2% 4.4% 4.4% 3.9% 4.0% 4.3% 4.5% 3.3% 3.34%
Growth Quality
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Revenue Stability 0.99 1.00 0.99 0.98 0.95 0.96 0.96 0.94 0.92 0.93 0.94 0.93 0.94 0.95 0.97 0.97 0.96 0.94 0.99 0.99 0.985
Earnings Stability 0.22 0.24 0.03 0.05 0.18 0.18 0.01 0.04 0.01 0.01 0.03 0.09 0.16 0.05 0.33 0.34 0.51 0.64 0.07 0.08 0.079
Margin Stability 0.91 0.89 0.89 0.89 0.88 0.88 0.86 0.84 0.82 0.82 0.82 0.82 0.83 0.84 0.85 0.86 0.87 0.87 0.87 0.87 0.873
Rev. Growth Consistency 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.00 1.00 1.00 1.000
Earn. Growth Consistency 0.50 0.50 1.00 0.00 0.00 0.00 0.00 0.00 0.50 0.50 0.50 0.50 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.000
FCF Positive Streak 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 0 0
Earnings Persistence 0.20 0.20 0.50 0.50 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.50 0.50 0.50 0.50 0.50 0.50 0.90 0.89 0.892
Earnings Smoothness 0.85 0.15 0.82 0.00 0.00 0.31 0.05 0.41 0.78 0.76 0.763
ROE Trend 0.97 1.27 0.69 0.26 -0.53
Gross Margin Trend -0.00 -0.00 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.00 -0.00 -0.00 -0.00 -0.00 0.00 0.00 0.00 0.00 0.00 0.002
FCF Margin Trend -0.00 -0.00 -0.01 -0.01 -0.01 0.00 0.01 0.00 0.02 -0.00 0.00 0.01 -0.00 0.00 -0.01 -0.02 -0.01 -0.00 0.01 0.02 0.016
Sustainable Growth Rate 14.2% 2.1% 31.2% -1.0% -12.9%
Internal Growth Rate 1.4% 0.1% 1.3% 0.3% 0.1% 0.8% 1.8% 1.9% 2.5% 2.2% 2.3% 2.4% 2.44%
Cash Flow Quality
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
OCF/Net Income 1.74 3.98 1.33 2.69 -0.83 -3.35 -3.47 -2.51 10.74 10.88 24.06 6.16 4.59 4.40 1.23 0.00 1.89 1.54 3.15 3.66 3.663
FCF/OCF 0.80 0.84 0.74 0.75 0.56 0.88 0.90 0.87 0.91 0.83 0.85 0.86 0.79 0.86 0.68 -163.67 0.83 0.77 0.89 0.90 0.902
FCF/Net Income snapshot only 3.305
OCF/EBITDA snapshot only 1.889
CapEx/Revenue 0.3% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.24%
CapEx/Depreciation snapshot only 0.733
Accruals Ratio -0.02 -0.04 -0.01 -0.02 -0.04 -0.09 -0.11 -0.10 -0.10 -0.06 -0.07 -0.08 -0.05 -0.07 -0.01 0.03 -0.03 -0.02 -0.07 -0.09 -0.090
Sloan Accruals snapshot only -0.053
Cash Flow Adequacy snapshot only 5.589
Earnings Quality Score snapshot only 0.750
Dividends & Buybacks
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Dividend Yield 3.6% 3.8% 4.4% 4.3% 3.9% 4.2% 3.2% 2.8% 2.9% 2.3% 2.5% 2.1% 1.9% 2.1% 1.9% 1.7% 1.5% 1.2% 1.3% 1.0% 1.02%
Dividend/Share $1.95 $1.96 $1.99 $2.04 $2.06 $2.03 $2.02 $2.07 $2.07 $2.07 $2.06 $2.07 $2.05 $2.04 $2.02 $2.03 $2.06 $2.06 $2.07 $2.09 $2.04
Payout Ratio 49.8% 93.8% 50.7% 1.0% 1.2% 2.0% 3.7% 79.9% 91.0% 58.5% 38.7% 37.6% 31.8% 31.6% 31.0% 29.7% 29.71%
FCF Payout Ratio 35.9% 28.2% 51.2% 51.0% 1.3% 20.4% 16.2% 19.4% 11.7% 22.3% 18.1% 15.0% 25.1% 15.4% 46.2% 20.3% 26.7% 11.1% 9.0% 8.99%
Total Payout Ratio 67.2% 1.3% 1.1% 2.8% 4.4% 9.7% 14.5% 3.2% 3.2% 1.5% 87.5% 67.3% 80.9% 31.6% 31.0% 51.8% 51.80%
Div. Increase Streak 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Chowder Number 0.04 0.04 0.06 0.05 0.03 0.02 -0.01 -0.03 -0.03 -0.04 -0.04 -0.04 -0.04 -0.03 -0.02 -0.01 0.00 0.00 0.01 0.01 0.012
Buyback Yield 1.3% 1.3% 5.4% 7.5% 6.9% 7.4% 8.7% 7.6% 8.0% 8.7% 7.2% 6.2% 4.7% 3.2% 2.4% 1.4% 2.3% 0.0% 0.0% 0.8% 0.76%
Net Buyback Yield 1.3% 1.3% 5.4% 7.5% 6.9% 7.4% 8.7% 7.6% 8.0% 8.7% 7.2% 6.2% 4.7% 3.2% 2.4% 1.4% 2.3% 0.0% 0.0% 0.8% 0.76%
Total Shareholder Return 4.8% 5.1% 9.8% 11.8% 10.8% 11.5% 11.9% 10.4% 10.9% 10.9% 9.7% 8.3% 6.5% 5.3% 4.2% 3.1% 3.8% 1.2% 1.3% 1.8% 1.78%
DuPont Factors
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Tax Burden (NI/EBT) 1.13 1.89 0.84 -12.33 1.53 1.21 1.06 6.62 0.95 0.41 0.29 0.56 0.59 0.71 0.72 0.73 0.74 0.74 0.74 0.73 0.732
Interest Burden (EBT/EBIT) 0.85 0.64 0.89 -0.37 1.34 1.24 1.15 2.74 0.81 0.87 0.86 0.95 0.94 0.97 0.97 0.95 0.94 0.91 0.89 0.94 0.942
EBIT Margin 0.01 0.00 0.01 0.00 -0.00 -0.00 -0.00 -0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.010
Asset Turnover 3.83 3.81 3.93 4.02 4.15 4.11 4.23 4.37 4.50 4.70 4.82 4.95 5.05 5.12 5.07 5.02 5.02 4.53 4.77 4.98 4.977
Equity Multiplier 10.07 23.80 23.80 23.80 23.80 81.64 81.64 81.64 81.64 -23.79 -23.79 -23.79 -23.79 -14.34 -14.34 -14.34 -14.34 -16.39 -16.39 -16.39 -16.390
Per Share
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
EPS (Diluted TTM) $3.91 $2.09 $3.93 $1.98 $-3.47 $-3.39 $-4.00 $-4.87 $1.79 $1.03 $0.56 $2.59 $2.26 $3.48 $5.23 $5.40 $6.46 $6.50 $6.67 $7.03 $7.03
Book Value/Share $6.09 $6.11 $6.20 $6.37 $6.51 $-2.58 $-2.60 $-2.72 $-2.75 $-11.65 $-11.83 $-12.02 $-12.07 $-13.11 $-13.11 $-13.22 $-13.33 $-11.59 $-11.64 $-11.73 $-11.37
Tangible Book/Share $-32.27 $-28.34 $-28.73 $-29.55 $-30.19 $-30.32 $-30.54 $-31.95 $-32.32 $-35.60 $-36.17 $-36.76 $-36.91 $-39.44 $-39.44 $-39.77 $-40.10 $-62.33 $-62.59 $-63.11 $-63.11
Revenue/Share $532.55 $554.49 $579.13 $609.56 $643.08 $659.51 $684.98 $739.51 $770.01 $807.13 $840.24 $878.18 $899.64 $925.18 $915.49 $914.06 $921.69 $927.41 $980.38 $1031.59 $1066.17
FCF/Share $5.42 $6.92 $3.89 $4.00 $1.62 $9.95 $12.46 $10.70 $17.62 $9.28 $11.36 $13.80 $8.18 $13.25 $4.38 $-2.02 $10.12 $7.71 $18.63 $23.23 $18.69
OCF/Share $6.82 $8.29 $5.24 $5.31 $2.89 $11.35 $13.89 $12.23 $19.28 $11.18 $13.38 $15.96 $10.36 $15.33 $6.46 $0.01 $12.23 $9.99 $20.99 $25.75 $21.31
Cash/Share $9.43 $11.63 $11.79 $12.12 $12.39 $17.15 $17.28 $18.07 $18.28 $16.05 $16.30 $16.57 $16.64 $20.95 $20.95 $21.12 $21.30 $16.14 $16.21 $16.35 $16.75
EBITDA/Share $6.91 $4.39 $7.88 $2.96 $0.84 $0.26 $-0.73 $2.42 $5.02 $5.60 $5.02 $7.67 $6.89 $7.98 $10.49 $10.77 $12.52 $12.94 $13.65 $13.63 $13.63
Debt/Share $23.04 $22.92 $23.24 $23.90 $24.42 $21.11 $21.26 $22.24 $22.50 $20.38 $20.70 $21.04 $21.13 $22.89 $22.89 $23.08 $23.27 $38.94 $39.10 $39.43 $39.43
Net Debt/Share $13.62 $11.29 $11.45 $11.77 $12.03 $3.96 $3.99 $4.17 $4.22 $4.33 $4.40 $4.47 $4.49 $1.94 $1.94 $1.96 $1.98 $22.80 $22.89 $23.08 $23.08
Academic Models
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Altman Z-Score 5.239
Altman Z-Prime snapshot only 0.957
Piotroski F-Score 7 8 8 7 6 4 4 4 6 7 6 6 6 7 8 7 7 7 6 7 7
Beneish M-Score -2.58 -2.47 -2.36 -2.42 -2.48 -2.84 -2.86 -2.84 -2.87 -2.77 -2.82 -2.84 -2.71 -2.60 -2.48 -2.29 -2.57 -2.32 -2.40 -2.49 -2.486
Ohlson O-Score snapshot only -6.950
Net-Net WC snapshot only $-81.78
EVA snapshot only $1595430390.87
Credit
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Credit Rating snapshot only B-
Credit Score 66.74 59.14 66.42 42.89 41.18 48.72 64.71 51.43 76.14 76.11 78.02 88.45 82.12 89.38 73.67 65.79 80.20 20.00 20.00 20.00 20.000
Credit Grade snapshot only 16
Credit Trend snapshot only -45.786
Implied Spread (bps) snapshot only 900.000
Industry Credit Rank snapshot only 84
Sector Credit Rank snapshot only 80

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms